Retinoids in skin cancer and hyperproliferative skin disease.
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D001565:Benzoates / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D006168:Guinea Pigs; D006801:Humans; D006965:Hyperplasia / Q000139:chemically induced; D066298:In Vitro Techniques; D015474:Isotretinoin; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control; D011817:Rabbits; D012176:Retinoids; D012867:Skin / Q000187:drug effects / Q000473:pathology; D012878:Skin Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D014212:Tretinoin / Q000494:pharmacology; D014801:Vitamin A / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001565:Benzoates; D012176:Retinoids; D014801:Vitamin A; D014212:Tretinoin; D015127:9,10-Dimethyl-1,2-benzanthracene; C034814:ethyl-p-((E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-1-propenyl)benzoic acid; D015474:Isotretinoin